Transgender Women, Join Our Research Study!
Researchers at Johns Hopkins University are exploring the relationship between HIV prevention medication and gender-affirming hormone therapy (GAHT).
Conducted at Johns Hopkins Hospital
Compensation
Provided
18 Years and Older
Transgender Women
HIV Negative
Fast Facts
About this research study:
Johns Hopkins researchers are conducting a research study examining the effects of pre-exposure prophylaxis (PrEP) in transgender women using gender-affirming hormones.

Transgender women face a higher risk of contracting HIV compared to the general population. However, the interactions between PrEP (a medication people take to prevent getting HIV) and gender-affirming hormone therapy (GAHT) are not fully understood.

The purpose of this research study is to evaluate the relationship between PrEP and GAHT. Qualified participants may receive up to $3,650 in compensation for their time after completing this 3-month study, which will include in-person visits and daily phone calls. Help advance clinical research and join our paid study today!

Principal Investigator: Mark Marzinke
JHM IRB# (IRB00203162)
Additional Information